SEPAR’s voice

Diagnosis and Treatment of Drug-Resistant Tuberculosis

José A. Caminero, a,b,c,* Joan A. Cayla, c,d José-Maria García-García, c,e Francisco J. García-Pérez, c,f Juan J. Palacios, c,g Juan Ruiz-Manzano c,h,i

a Servicio de Neumología, Hospital General de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
b Unidad de Tuberculosis con Multi-Drogo Resistencia, Unión Internacional contra la Tuberculosis y Enfermedades Respiratorias (La Unión), París, France
c Programa Integrado de Investigación en Tuberculosis (PI TB) de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Barcelona, Spain
d Servicio de Epidemiología, Agencia de Salud Pública de Barcelona, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
e Unidad de Gestión Clínica de Neumología, Hospital Universitario San Agustín, Avilés, Asturias, Spain
f Servicio de Neumología, Hospital Universitario de La Princesa, Madrid, Spain
g Unidad de Referencia Regional de Micolobacterias, Servicio de Microbiología, Hospital Universitario Central de Asturias, Oviedo, Spain
h Servicio de Neumología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
i Ciber de Enfermedades Respiratorias (CIBERS), Barcelona, Spain

ARTICLE INFO

Article history:
Received 30 November 2016
Accepted 12 February 2017
Available online 31 July 2017

Keywords:
Drug-resistant tuberculosis
Multi-drug-resistant tuberculosis
Extremely drug-resistant tuberculosis
Diagnosis
Treatment

ABSTRACT

In the last 2 decades, drug-resistant tuberculosis has become a threat and a challenge to worldwide public health. The diagnosis and treatment of these forms of tuberculosis are much more complex and prognosis clearly worsens as the resistance pattern intensifies. Nevertheless, it is important to remember that with the appropriatesystematic clinical management, most of these patients can be cured.

These guidelines itemize the basis for the diagnosis and treatment of all tuberculosis patients, from those infected by strains that are sensitive to all drugs, to those who are extensively drug-resistant. Specific recommendations are given for all cases. The current and future role of new molecular methods for detecting resistance, shorter multi-drug-resistant tuberculosis regimens, and new drugs with activity against Mycobacterium tuberculosis are also addressed.

© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos

RESUMEN

En las últimas 2 décadas la tuberculosis con resistencia a fármacos se ha convertido en una amenaza y un reto para la salud pública mundial. El diagnóstico y el tratamiento de estas formas de tuberculosis es mucho más complejo, y el pronóstico empeora claramente a medida que se incrementa el patrón de las resistencias. Sin embargo, es necesario destacar cómo con el manejo clínico y programático adecuado de estos enfermos se puede conseguir la curación de una mayoría de ellos.

En esta normativa se razonan las bases del diagnóstico y tratamiento de todos los pacientes afectos de tuberculosis, desde aquellos que tienen formas de la enfermedad con sensibilidad a todos los fármacos hasta aquellos que son portadores de los patrones más extensos de resistencia. Asimismo, se dan recomendaciones específicas para cada uno de estos supuestos. También se aborda el papel que ya están teniendo y pueden tener en un futuro inmediato los nuevos métodos moleculares de detección de resistencias, los esquemas acortados de tratamiento de la tuberculosis multi-farmacorresistente (TB-MDR) y los nuevos fármacos con actividad frente a Mycobacterium tuberculosis.

© 2017 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.


* Corresponding author.
E-mail address: jcamlun@gobiernodecanarias.org (J.A. Caminero).

1579-2129/© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.
**Introduction and Rationale for the Guidelines**

After decades during which tuberculosis (TB) became an almost universally curable disease, the emergence of strains of *Mycobacterium tuberculosis* (*M. tuberculosis*) resistant to the most active drugs available has once again made TB a major threat and a challenge to global public health. It is, however, important to remember that if access to appropriate diagnosis and treatment are guaranteed, the chances of curing all patients with TB are very high, even among carriers of highly resistant strains. Protocolized clinical management is essential if the treatment of these patients is to be successful.\(^2\)–\(^9\)

The current global status of multidrug-resistant TB (MDR-TB) – TB resistant to at least isoniazid (H) and rifampicin (R) – is worrying, and the overall response to this situation has been unsatisfactory.\(^1\),\(^10\) An estimated 3.9% of new TB cases worldwide are thought to be MDR-TB, and this rate rises to 21% in previously treated patients.\(^1\) Of the estimated 10.6 million cases of TB occurring in 2015 (1.8 million deaths), about 580,000 cases may have been rifampicin-resistant (RR-TB) or MDR-TB, leading to around 250,000 deaths.\(^1\) Worldwide, however, less than 150,000 cases (26% of the estimated total) were reported, with a cure rate of 52%.\(^1\) In other words, only about 10% of the estimated MDR-TB patients worldwide were cured, a rate that is totally ineffective for controlling the epidemic.

Although the prevalence of MDR-TB in Spain remains difficult to pinpoint due to underreporting of TB and failure to perform systematic resistance testing, the situation seems more favorable: 0.1% cases of TB in Spanish natives and 2.2% in immigrants were primary MDR-TB, of which 3.4% and 10.2%, respectively, showed primary resistance to H,\(^11\),\(^12\)

**Diagnosis of Drug-Resistant Tuberculosis**

TB diagnosis is still based on clinical suspicion, radiology, and microbiological testing.\(^13\) The clinical and radiological features of drug-resistant tuberculosis (DR-TB) are indistinguishable from those of drug-susceptible TB, so diagnosis of DR-TB must always be based on microbiological and/or molecular evidence.\(^5\)

**Drug Susceptibility Studies**

Spanish guidelines currently recommend cultures and susceptibility studies, including at least isoniazid (H) and rifampicin (R), in all patients with TB, irrespective of whether the patient is treatment-naive or presents a risk factor for DR-TB (Table 1)\(^1\),\(^15\),\(^16\),\(^17\) (strong recommendation, high quality of evidence [⊕⊕⊕⊕]).

If resistance to R is shown, the susceptibility study should be extended to include the fluoroquinolone (FQ) and the second-line injectable drug (SLID) that will be used in the rescue treatment offered to the patient\(^6\) \[(levofloxacin [Lfx]/moxifloxacin [Mfx] and amikacin [Am]/capreomycin [Cm] in Spain) \] (conditional recommendation, moderate quality of evidence [⊕⊕]).

The results of conventional susceptibility testing to all these drugs are very reliable, so this information can be used to guide the recommended treatment regimen. In contrast, the clinical credibility of susceptibility testing to other drugs such as ethambutol (E), pyrazinamide (Z), ethionamide/prothionamide (Eth/Pth), cycloserine (Cs), para-aminosalicylic acid (PAS), or clofazimine (Cfz) is significantly lower, and these results can often confound rather than assist decisions regarding the possible treatment regimen needed by the patient. For this reason, routine testing is not recommended, and if these tests are performed, the results must be viewed with caution\(^6\),\(^16\),\(^18\) (conditional recommendation, low [⊕⊤] to very low [⊕] quality of evidence).

**Phenotypic and Genotypic Drug Susceptibility Testing**

Susceptibility tests can be performed using phenotypic or genotypic methods. Phenotypic testing must be performed on mycobacteria in active growth phase in the culture media, so results will be unavailable for at least 2–3 weeks if liquid media are used, and up to 4–8 weeks in the case of solid media.\(^5\) This delay may be excessive if a decision is to be made regarding the ideal treatment of the patient.

In contrast, molecular tests, which use genetic amplification techniques to detect mutations in genes coding for resistance to anti-TB drugs, provide results within 24–48 h. For this reason, such tests, when available, should be performed in all patients diagnosed with TB (strong recommendation, high quality of evidence [⊕⊕⊕⊕]).

**Specific Molecular Techniques: Xpert MTB/RIF (Cepheid) and GenotypeMDRplus (Hain)**

One of the most important of these molecular techniques is the Xpert MTB/RIF (Cepheid) that can detect resistance to R within 2 h with a sensitivity of 95% and a specificity of 98%.\(^14\),\(^17\) This technique is much more sensitive than sputum smears (positive in up to 70%–90% of cases with negative smear test and positive culture), and represents an important advance in early detection. The GenotypeMDRplus (Hain) or line probe assay can also simultaneously detect mutations in genes that encode resistance to isoniazid (*katG* and *inhA*) and rifampicin (*rpoB*) within a period of 6–24 h.\(^19\),\(^20\)

Both molecular techniques can be carried out in direct samples, without the need to wait for the isolate to grow in culture. The clinical significance of the *inh A* gene mutation and/or the *katG* gene and the recommendation to use H despite proven resistance are described in detail in the online version of this guideline.\(^21\)–\(^28\)

Version 2 of the GenotypeMDRsl (Hain) line probe assay can be used to detect resistance to FQ (gyrA and gyrB mutations) and to SLID (genetic mutations in *rrs* and the *eis* promoter region). The specificity of this method for both FQs and SLID is higher than 98%,\(^29\)–\(^31\) so this information should be taken into consideration in the design of the treatment schedule\(^22\),\(^33\) (conditional recommendation, moderate quality of evidence [⊕⊕]).

**Clinical History of Previously Administered Drugs**

It is of utmost importance to consult the clinical records of patients previously treated for TB to determine their drug history.\(^5\) When the wrong drug has been administered for more than 1 month, the possibility of resistance and reduced efficacy must be suspected, even if the susceptibility testing suggests the opposite.\(^3\),\(^34\) There are simple drug history templates that can help with this task, as shown in Fig. 1.\(^5\) It is also necessary to determine if the patient’s index case had DR-TB.

**Diagnosis of Drug-Resistant Tuberculosis: Conclusions**

This guideline recommends that: (1) all patients with diagnosis of TB undergo H and R susceptibility testing, using a rapid test molecular if available; (2) if resistance to R and/or H is demonstrated, susceptibility tests to the FQ and SLID proposed for the subsequent treatment schedule should be performed, using GenotypeMDRsl (Hain) \(\approx 2\) if possible; (3) standard phenotypic tests must also be performed; while these take longer and support the treatment decision to a lesser degree, they can resolve any discrepancies between the methods; and (4) a clinical drug history is essential for designing future treatment regimens.
Principles for the Treatment of Both Drug-Susceptible and Drug-Resistant Forms of Tuberculosis

All TB treatment must meet 2 basic bacteriological requirements: drugs must be combined to prevent the selection of resistance and the treatment must be administered for long enough to ensure cure and avoid relapses.\(^6,35,36\)

To ensure cure of TB without relapse as far as possible, it is recommended that all treatment regimens involve a combination of at least 4 previously unused drugs or drugs to which the \textit{M. tuberculosis} has shown susceptibility.\(^6,15,36\) Of these, 2 must be core drugs, capable of eliminating the majority of the bacilli and curing the patient. At least 1 of these core drugs must have good bactericidal activity (ability to eliminate rapidly multiplying bacilli located in cavitated lesions that cause symptoms and transmission), and at least 1 must have good sterilizing activity (ability to eliminate those bacilli in semiliquid phases that are responsible for relapses). The other 2 drugs are what we call companion compounds, and their mission is to protect the core drugs from selection of resistance (conditional recommendation, moderate quality of evidence [⊕⊕⊕]).

To assist in the selection of the drugs needed to make up a TB regimen, \textit{Fig. 2} shows the bactericidal and sterilizing capacity of the different drugs, their ability to prevent the selection of resistance, and their toxicity profile.\(^36\)

\textit{Tables 2a and 2b} list in detail the doses of the different drugs with activity against \textit{M. tuberculosis}, the route of administration, and the most common adverse effects.

Rational Classification of Drugs With Activity Against \textit{M. tuberculosis}

To assist in the selection of the 4 drugs that must be included in any treatment of initial phase TB, these compounds should be classified into 5 different groups (Table 3), starting with Group 1, the group with the greatest activity, and continuing with the others in decreasing order of effectiveness and tolerance.\(^3,8,37,38\) Prescribing physicians should work their way down through these groups until at least 4 new drugs or drugs very likely to be susceptible have been combined, ensuring the inclusion of at least 1 bactericidal drug and 1 sterilizing drug. Guidelines for starting each of the drugs included in these groups are shown in Table 3 (conditional recommendation, moderate quality of evidence [⊕⊕⊕]).

Group 1 consists of "first-line oral drugs", so called because these are used in the first instance in practically all patients with drug-susceptible TB. This group comprises the most effective, the
Activity and toxicity of anti-TB drugs

Fig. 2. Characteristics of drugs with activity against M. tuberculosis. Adapted from Caminero et al.36 Prevention of resistance, bactericidal activity and sterilizing activity are listed in descending order (high, moderate, and low activity), while toxicity (right-hand arrow) is listed in ascending order (low, moderate, high), so that the best available drugs combining all these features appear in the top row.

Table 2a
Drugs With Anti-M. tuberculosis Activity. Recommended Doses and Most Common Adverse Effects (a, Recommended Doses for Each of the Drugs Used Individually).

<table>
<thead>
<tr>
<th>Drug</th>
<th>Route</th>
<th>Dose</th>
<th>Most Common Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rifampicin</td>
<td>Oral, IV</td>
<td>10 mg/kg, Max. 600 mg</td>
<td>Hepatitis, hypersensitivity reactions</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>Oral, IV, IM</td>
<td>5 mg/kg at normal doses (max. 300 mg)</td>
<td>Hepatitis. Peripheral neuritis</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>Oral</td>
<td>25–30 mg/kg</td>
<td>Hepatitis. Hyperuricemia</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>Oral</td>
<td>25 mg/kg 15 mg/kg in continuation phase</td>
<td>Optic neuritis</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>IM, IV</td>
<td>15 mg/kg. 1 g</td>
<td>Nephrotoxicity, 8th cranial nerve involvement</td>
</tr>
<tr>
<td>Ethionamide/prothionamide</td>
<td>Oral</td>
<td>750–1000 mg</td>
<td>Gastroenteritis/hepatitis</td>
</tr>
<tr>
<td>Cycloserine</td>
<td>Oral</td>
<td>750–1000 mg</td>
<td>Personality changes/depression</td>
</tr>
<tr>
<td>Capreomycin</td>
<td>IM, IV</td>
<td>15 mg/kg Max. 0.75–1 g/day or/48 h</td>
<td>Ototoxicity/nephrotoxicity</td>
</tr>
<tr>
<td>Kanamycin</td>
<td>IM, IV</td>
<td>15 mg/kg Max. 0.75–1 g/24 h or/48 h</td>
<td>Ototoxicity/nephrotoxicity</td>
</tr>
<tr>
<td>Amikacin</td>
<td>IM, IV</td>
<td>15 mg/kg Max. 0.75–1 g/24 h or 48 h</td>
<td>Ototoxicity/nephrotoxicity</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>Oral, IV</td>
<td>15 mg/kg – 750 mg&lt;sup&gt;3&lt;/sup&gt; g</td>
<td>Tenosynovitis</td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>Oral</td>
<td>400–800 mg</td>
<td>Tenosynovitis</td>
</tr>
<tr>
<td>PAS</td>
<td>Oral</td>
<td>10–15 g</td>
<td>Gastroenteritis/hepatitis</td>
</tr>
<tr>
<td>Clofazimine</td>
<td>Oral</td>
<td>100–200 mg</td>
<td>Pigmentation/eosinophilic enteritis</td>
</tr>
<tr>
<td>Linezolid</td>
<td>Oral, IV</td>
<td>600 mg</td>
<td>Pancytopenia/gastrointestinal disorders/polynuerosis</td>
</tr>
<tr>
<td>Meropenem</td>
<td>IV</td>
<td>1 g/8 h or 12 h</td>
<td>Hematological disorders</td>
</tr>
<tr>
<td>Bedaquiline</td>
<td>Oral</td>
<td>400 mg/day for 15 days and then 200 mg/3 times a week for a maximum of 6 months</td>
<td>Gastric intolerance, pancreatitis, hepatitis, altered QTC on ECG</td>
</tr>
<tr>
<td>Delamanid</td>
<td>Oral</td>
<td>100 mg/12 h for a maximum of 6 months</td>
<td>Anemia, nausea, altered QTC on ECG</td>
</tr>
</tbody>
</table>

best tolerated, and the least expensive products.37,38 Drugs classified as core because of their bactericidal (H and R) or sterilizing (R and Z) activity must be distinguished from companion drugs (E).6,36

Group 2 consists of the FQs (high-dose Lfx or Mfx), which are also core drugs with bactericidal and sterilizing activity and low toxicity.5,37,38 Moreover, if these products can be used, they clearly affect prognosis in the treatment of MDR-TB.5,39,40 Although no specific studies have been performed, evidence suggests the presence of considerable cross-resistance between these two FQs.

Group 3 consists of second-line injectable drugs. These are also core drugs, due to their bactericidal activity, but with little or no sterilizing ability and they are far more toxic than the FQs.6,37,38 This cumulative toxicity and the need for administration by injection greatly limit their use.

Group 4 is composed of 6 different drugs that might be administered in combination because they attack M. tuberculosis via different targets.3,4,6,37,38 This is a mixed group consisting of drugs that could be considered core due to their activity, although the accumulated evidence is still scant (linezolid, bedaquiline and delamanid), and others that have stronger supporting evidence but moderate or low activity (ethionamide/prothionamide and cycloserine/terizidone) and would behave as companion drugs, and a third, clofazimine, which seems to have good sterilizing activity. The selection of one or the other will depend on their availability and possible adverse effects.

Linezolid can be considered a core drug, with bactericidal and sterilizing activity.38 Several publications38,41–43 have confirmed its role in the treatment of MDR-TB and extensively drug resistant TB (XDR-TB). Linezolid has 2 drawbacks, namely its cost and its toxicity profile when administered for more than 6–8 weeks, with frequent hematological alterations and polyneuropathies. Toxicity problems are highly dose-dependent38 and relatively easy to manage, given the low dose recommended for MDR-TB,38,41 while the price has fallen since the generic molecule became available in 2016.
Langet's work on the use of delamanid (a newer TB drug) is highlighted.

Table 2b: Drugs With Anti-M. tuberculosis Activity, Recommended Doses and Most Common Adverse Effects (b, Recommended Doses for Combinations of the Most Common Drugs Available in Spain).

<table>
<thead>
<tr>
<th>Combination isoniazid+rifampicin (H+R)</th>
<th>Rifabutin 300™ (H 150 mg, R 300 mg).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients weighing 30–50 kg</td>
<td>1 tab./day</td>
</tr>
<tr>
<td>Patients 50 kg or more</td>
<td>2 tab./day</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Combination isoniazid+rifampicin+pyrazinamide (H+R+Z)</th>
<th>Rifabutin™ (H 50 mg, R 120 mg, Z 300 mg).</th>
</tr>
</thead>
<tbody>
<tr>
<td>In children under the age of 10 years, adjust according to dose</td>
<td></td>
</tr>
<tr>
<td>Patients weighing 20–30 kg</td>
<td>2 tab./day</td>
</tr>
<tr>
<td>Patients weighing 30–40 kg</td>
<td>3 tab./day</td>
</tr>
<tr>
<td>Patients weighing 40–49 kg</td>
<td>4 tab./day</td>
</tr>
<tr>
<td>Patients weighing 50–64 kg</td>
<td>5 tab./day</td>
</tr>
<tr>
<td>Patients 65 kg or more</td>
<td>6 tab./day</td>
</tr>
</tbody>
</table>

**Combination isoniazid+rifampicin+pyrazinamide+ethambutol (H+R+Z+E)**

<table>
<thead>
<tr>
<th>Combination isoniazid+rifampicin+pyrazinamide+ethambutol (H+R+Z+E)</th>
<th>Rimixan™ (H 75 mg, R 150 mg, Z 400 mg, E 275 mg).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients weighing 30–39 kg</td>
<td>2 tab./day</td>
</tr>
<tr>
<td>Patients weighing 40–54 kg</td>
<td>3 tab./day</td>
</tr>
<tr>
<td>Patients weighing 55–70 kg</td>
<td>4 tab./day</td>
</tr>
<tr>
<td>Patients 70 kg or more</td>
<td>5 tab./day</td>
</tr>
</tbody>
</table>

**Sources:** World Health Organization; World Health Organization; Lange et al.; Caminero et al.

**Table 3: Rational Classification and Sequential Use of Anti-TB Drugs When Designing a Treatment Regimen for Drug-Susceptible or Drug Resistant TB.**

**First-line drugs for oral administration**
- Core drugs: isoniazid, rifampicin, pyrazinamide
- Companion drug: ethambutol

**Fluoroquinolones**
- High-dose levofloxacin or moxifloxacin, all are core

**Second-line injectable drugs**
- Streptomycin, kanamycin, amikacin, capreomycin, all are core

**Mixed group of core drugs with little evidence and less effective companion drugs**
- Rifampicin, pyrazinamide, thiacetazone
- Other drugs with less clinical experience, or less effective and more toxic:
  - Carbapenems (meropenem/imipenem), amoxicillin/clavulanic acid, PAS, clofazimine, thiacetazone

**Sources:** World Health Organization; Caminero et al.; World Health Organization; Caminero et al.; Caminero et al.

**Table 3a: Rational Classification and Sequential Use of Anti-TB Drugs When Designing a Treatment Regimen for Drug-Susceptible or Drug Resistant TB.**

Bedaquiline can also be considered core drug due to its bactericidal and sterilizing activity. Two clinical trials have demonstrated its efficacy in the treatment of MDR-TB, particularly in XDR-TB (a drug-resistant strain) and in children. Finally, delamanid pretreatment and pretreatment with metronidazole with pretreatment and sterilizing activity. Two randomized clinical trials have demonstrated the usefulness of delamanid in the treatment of MDR-TB, particularly in XDR-TB.

Linanazid, bedaquiline, and delamanid are all likely to play a significant role in the treatment of MDR-TB in the very near future, and may also be of use in the treatment of susceptible TB.

Aside from the foregoing drugs, the most effective compounds are the thiocarboxylic amidines (ethionamide/thionamide). These may be mildly bactericidal, but show potential cross-resistance with fluoroquinolones and a poor gastric tolerance profile. The next most active is clofazimine, which can be used as an important component of short treatments of MDR-TB due to its possible sterilizing activity. The last is cycloserine (similar to terizidone in terms of action), which has good oral tolerance, but limited activity and potentially serious psychiatric adverse effects.

A hypothetical Group 5 would include the carbapenems (imipenem or meropenem) combined with clavulanic acid (as this does not exist separately, it must be administered with amoxicillin), which are probably quite active despite the scant supporting evidence. PAS, which is very ineffective, with poor gastric tolerance and thioacetazone, which is very weak, potentially toxic in patients with human immunodeficiency virus (HIV), and very difficult to obtain.

**Treatment of Tuberculosis According to Resistance Patterns**

TB, according to possible resistance patterns, difficulty of treatment and the different prognoses involved, can be classified into 5 large groups in ascending order of complexity (Table 4).

**Primary Tuberculosis Susceptible to All Anti-TB Drugs**

The ideal treatment regimen for new TB cases in which susceptibility to all drugs is assumed would be 2HRZE/4HR, taking into consideration the factors listed in Table 4. The possibility of errors and selection of resistance, these drugs should be administered in fixed dose combinations (Tables 2a and 2b) with directly observed therapy in patients with risk factors for poor treatment compliance.

**Treatment of Tuberculosis Resistant to Isoniazid (Single or Multiple Resistances) but Susceptible to Rifampicin**

This is a relatively common situation. In these cases, the recommendation is to use 9 HRZE (in this case, high doses of H may be considered), and to perform a susceptibility study with the remaining first-line drugs (conditional recommendation, low [±θ] to very low [θ] quality of evidence). A regimen containing 2FQ/REZ/7CF–RE could also be considered (with an FQ susceptibility study), but FQ (Lfx/Mfx) should only be included if it is administered from the beginning of treatment along with the other drugs. It should not be added if results of resistance testing to H are received after 3–4 weeks of treatment, due to possible risk of drug interactions. See options in Table 4. A third possibility, in line with current SEPAR recommendations is 2RZE/10RE, which has been used successfully in standard treatments where H had to be discontinued due to intolerance.

**Treatment of Tuberculosis Resistant to Rifampicin (Single or Multiple Resistances), but Susceptible to Isoniazid**

As cases of isolated resistance to R are very rare in clinical practice, and since R is the compound that determines prognosis in patients with MDR-TB, these patients should be approached as MDR-TB cases, and treated as such, with the addition of H to the schedule, of course, because if susceptibility is confirmed, this...
Table 4
Recommended Basic Regimens for Patients With Susceptible TB and Single or Multiple Resistances.

<table>
<thead>
<tr>
<th>TB cases resistant to H (single or multiple resistances), but susceptible to R</th>
<th>9HRZE, or 2FQ–REZ/7FQ–RE or 2RZE/10RE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases resistant to R (single or multiple resistances) but susceptible to H</td>
<td>The total duration of this combination of 4 new drugs plus Z is much more controversial. The conventionally recommended regimens of more than 21 months have not achieved success rates greater than 55%–70%, particularly due to high drop-out rates, which are clearly associated with the extensive length of treatment, and also with poor tolerance and toxicity. For this reason, this guideline recommends that priority be given to the 9–12 month schedule recently recommended by the WHO for all patients with R-resistant TB, or with MDR-TB who have not previously received FQ or SLID, or who show susceptibility in vitro to these 2 classes of antibiotics (conditional recommendation, very low [Θ] quality of evidence). This regimen consists of an initial phase of 4 months (or until sputum smears become negative) with kanamycin (Am or Cm in Spain),</td>
</tr>
<tr>
<td>same treatment as MDR-TB, which is shown in Table 5, adding H to the regimen, but without counting it as one of the 4 new drugs</td>
<td></td>
</tr>
</tbody>
</table>

Sources: Caminero et al.; Caminero.

- There is no consensus with regard to the duration of this treatment in HIV-infected patients, and some groups and scientific societies recommend continuing treatment for 9 months, with the aim of reducing the relapse rate.
- Do not switch to the continuation phase (4 HR) until 1 of the following 2 circumstances occurs: sputum smear is negative, or susceptibility to H and R is confirmed.
- Prolong treatment beyond 6 months in patients whom sputum smears and/or cultures take longer than 2 months to become negative. As a reference, these patients will continue treatment with H+R for at least 4 months after cultures become negative.
- If the 9 HRZE regimen is selected, high doses of H will be given.
- FQ (Lfx/Mfx) should only be included in the regimen if it is administered with the rest of the drugs from the beginning. It should not be added if results of resistance testing to H are achieved after 3–4 weeks of treatment, due to the possible risk of de facto monotherapy. In this case, use 9 HRZE.

Table 5
Recommended Basic Regimens for Patients With MDR-TB.

<table>
<thead>
<tr>
<th>MDR-TB cases, but without resistance to second-line drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short regimen: (Cm/Am+Mfx+Pth/Eth+Clz+E+Z+H)’/5 (Mfx+Clz+E+Z)</td>
</tr>
<tr>
<td>Standard regimen: Intensive phase (Cm+Mfx/Lfx+Z+2 Group 4 drugs)’/continuation phase (Mfx/Lfx+Z+2 Group 4 drugs)’</td>
</tr>
<tr>
<td>MDR-TB cases with additional resistance to the FQ, SLID, both, or even broader XDR-TB resistance patterns</td>
</tr>
</tbody>
</table>

Consult experts and design a regimen that follows all the recommendations made in this guideline, looking for a minimum of 4 new drugs, following the rational classification provided (Groups 1 to 5), with the aim of including the maximum number of bactericidal and sterilizing drugs.

CP: continuation phase. Until completion of 21 months of treatment; IP: intensive phase. Until cultures become negative, or up to 6 months in case of extensive lesions. Continue for at least 4 months if the patient is not expecting and no follow-up sputum tests can be performed.

Sources: Caminero et al.; World Health Organization; Caminero.

- At least 4 months or until sputum smear testing becomes negative.
- High doses of Mfx (800 mg).
- High doses of H (15–20 mg/kg body weight).
- The injectable drug may be given 3 times per week (with an interval of 48 h between doses) when sputum smears become negative.
- Two Group 4 drugs will be chosen on the basis of availability and potential adverse effects.

Table 6
Follow-Up Required During TB Treatment.

<table>
<thead>
<tr>
<th>Control</th>
<th>M0</th>
<th>M1</th>
<th>M2</th>
<th>M3</th>
<th>M4</th>
<th>M5</th>
<th>M6</th>
<th>M7</th>
<th>M8</th>
<th>M9</th>
<th>M10</th>
<th>M11</th>
<th>+M12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical visit</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Sputum smear (&gt;2–3)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Culture (&gt;2–3)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Clinical laboratory tests</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>EKG</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ENT audiometry</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Chest radiograph</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Ophthalmological examination</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Psychiatric evaluation</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

- Optional in case of good clinical progress and negative sputum smear and culture at the end of the fourth month.
- Only if the patient is receiving high-dose moxifloxacin, delamanid and/or bedaquiline. If normal doses of moxifloxacin are given, a EKG every 2–3 months is sufficient.
- Only if the patient is treated with an injectable drug, either aminoglycoside or capreomycin.
- Only if the patient is receiving ethambutol and/or linezolid.
- Only if the patient is receiving cycloserine or terizidone.

will contribute significantly to the treatment (conditional recommendation, low [Θ] to very low [Θ] quality of evidence).

Treatment of Multi-Drug Resistant Tuberculosis Susceptible to Fluoroquinolones and Second-Line Injectable Drugs

Following the rationale of this guideline, the ideal regimen for these patients would include an FQ (Mfx, or high-dose Lfx), a second-line injectable drug (at least until cultures become negative), and 2 drugs selected from Group 4 of this guideline. Z should also be included in this regimen if susceptible, due to its possible activity, taking into account that the susceptibility test is not reliable (conditional recommendation, very low [Θ] quality of evidence). The options listed in Table 5 should be considered.
high-dose moxifloxacin, clofazimine, ethionamide/prothionamide, pyrazinamide, ethambutol, and high-dose H. The continuation phase will be of 5 months of high-dose moxifloxacin, clofazimine, ethambutol, and pyrazinamide. Patients must be closely monitored for possible adverse effects, primarily possible prolongation of the QTc interval on electrocardiogram, due in particular to the high moxifloxacin doses recommended in this regimen.
Treatment of Patients With Multi-Drug Resistant Tuberculosis and Added Resistance to Fluoroquinolones, Second-Line Injectable Drugs, or Both, or Even Broader Patterns of Resistance

The clinical and operational management of these forms of TB are already beset by several major difficulties. They must be treated by experts in the disease, in units that can guarantee close follow-up of treatment and appropriate management of adverse reactions. Possible regimens that can be administered to the vast majority of these patients are shown in Table 5.

Role of Surgery

Surgery can also contribute to the success of the treatment of MDR-TB, although it can only be considered in the few patients that meet the following 3 conditions: (1) reasonably localized resectable lesion; (2) sufficient respiratory reserve for the patient to tolerate surgery and the postoperative period; and (3) lack of medications available to design a curative regimen for the patient. If the last premise is met, surgery may be considered in patients with FQ-resistant MDR-TB or an even broader resistance pattern (conditional recommendation, very low [ العمر] quality of evidence).

Monitoring During Treatment and Evaluation of Results

Patients should be monitored at least once a month during the intensive treatment phase, and then every 1 or 2 months during the continuation phase. Aspects that should be evaluated in each of these controls are listed in Table 6, and criteria for evaluating treatment outcomes are described in detail in Table 7.

Management of Contacts

Available evidence suggests that if a contact of a case with MDR-TB develops TB, they should receive the same treatment as the index case while pending susceptibility test results, with possible subsequent adjustment after the test results are received. If the secondary case is not confirmed microbiologically, as can happen in children, in paucibacillary TB, or in extrapulmonary TB, the regimen of the index case must continue. Systematic treatment of the tubercular infection in contacts of MDR-TB patients is not recommended, unless they have another risk factor for MDR-TB.

Conclusions

Although TB resistances complicate treatment and the chances of success, following basic rules of management will ensure acceptable cure rates in the vast majority of patients. The basic principles and a summary of most of these guidelines can be found in Table 8. In all cases, an expert should be consulted when designing a treatment scheme for these patients. For this purpose, the foundation of national expert groups sponsored by the health authorities and/or the scientific societies is recommended. The first priority is still to offer patients with susceptible TB the appropriate treatment, in order to avoid the appearance of resistance.

Conflict of Interest

The authors state that they have no conflict of interest.

References

10. Organization WH. Drug-resistant tuberculosis surveillance & response. Supplemen
17. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmo
24. Katiyar SK, Bihari S, Prakash S, Mamanti M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculo